Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

PINEAL REGULATORLimited Evidence

Epithalon

Tetrapeptide · 10mg

Vial size

Status

Limited Evidence

Route

SubQ

Half-life

Short plasma half-life

Class

Synthetic tetrapeptide

MechanismTelomerase Activation / Circadian Modulation

Cohort54 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$55 USD/vial

À-la-carte: $60 USD/vial · Save 8%

Vials per allocation

Member total (1×)$55

À-la-carte total$60

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Khavinson tetrapeptide. Supports pineal-hypothalamic axis regulation and telomere maintenance via telomerase upregulation.

Tetrapeptide · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-04

Cellular - Energy & Longevity

Popular · Longevity & Cellular

Epithalon · Pineal Regulator

◆ Certificate of Analysis · Epithalon

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot-specific COAs for Epithalon are published with each batch release. Sample certificates available on request via partnerships@vivrelabs.com.

◉

Clinical Overview

Epithalon

Epithalon (also Epitalon) is a 4-amino-acid synthetic peptide developed by Russian gerontologist Vladimir Khavinson. Originally derived from study of bovine pineal extracts.

The most studied peptide bioregulator in longevity research, with multi-decade Russian clinical literature.

◷

Pineal/Circadian

Modulates pineal function and circadian hormone regulation.

❖

Telomerase Activity

Reported telomerase activation in vitro (Russian-origin research).

◈

Evidence Status

Evidence class limited; largely unreplicated outside originating groups.

◈

Mechanism

How It Works

Modulates pineal gland function and downstream regulation of melatonin and other circadian-axis hormones. Demonstrated to activate telomerase in human somatic cells, with corresponding telomere lengthening in laboratory studies.

Mechanism & evidence - the honest frame

Mechanism (single-group origin, now partially replicated): Epithalon (AEDG) is reported to induce telomerase (hTERT) activity and telomere elongation in cultured human somatic cells (Khavinson et al., Bull Exp Biol Med 2003) and to restore rhythmic melatonin in aging models. A 2025 independent study (Al-Dulaimi et al., Biogerontology) reproduced telomere lengthening via telomerase/ALT in human cell lines - validation outside the originating lab, though no quantitative human telomere figure is established (the often-cited ‘33%’ is not supported by a primary human study). Honest frame: most long-term/mortality data is a non-blinded, non-randomised Russian cohort program (~266 elderly) - not comparable to Western RCTs; no large Western RCT exists. Theoretical caution: telomerase activation could in principle accelerate a pre-existing pre-cancerous clone - a physician-screening point. - SLEEP/CIRCADIAN: unlike DSIP, Epithalon has no immediate sedative effect (taken at night it will not make you drowsy); its sleep relevance is structural - reported in aging models to restore rhythmic endogenous melatonin over weeks, a circadian repair rather than a same-night fix. The popular claim that it “rejuvenates the pineal gland” or guarantees months of better sleep overstates the evidence. Framing for patients: DSIP is the acute/same-night question; Epithalon is the long-term circadian-structure question - different problems, physician-determined.

✚

Patient Bloodwork Guide

Bloodwork for Longevity & Mitochondrial Protocols

Cellular / mitochondrial - SS-31, MOTS-c, Epithalon, NAD+, V-04

These protocols target cellular energy, mitochondrial function, and markers of biological aging. Monitoring here is less about week-to-week safety and more about confirming the protocol is moving the deeper markers it is meant to.

Incremental approach. V-04 is introduced in phases (structural support first, then signaling, then a short telomere overlay) at conservative doses. Re-testing at the 6-month mark is how progress is judged.

Biological-age markers

Horvath methylation clockAn epigenetic estimate of biological age - the headline longevity marker, retested over months.

Telomere lengthTracks cellular aging at the chromosome level.

Mitochondrial & oxidative

Lactate (fasting & post-exercise)Healthy mitochondria clear lactate quickly. A high or slow-clearing level suggests cells are leaning on less-efficient anaerobic energy; a downward trend over time points to improving mitochondrial efficiency.

Lipid-peroxidation markers (MDA, 4-HNE)Signals of oxidative damage to cell membranes. Relevant to SS-31, which works by protecting the mitochondrial membrane lipid (cardiolipin) - a fall in these markers is a sign that structural protection is taking hold.

Fasting insulin & HOMA-IRA measure of how efficiently muscle takes up glucose. Relevant to MOTS-c, which supports muscle glucose uptake via the AMPK pathway - improvement shows as lower fasting insulin and a lower HOMA-IR score.

8-OHdGA marker of oxidative stress / DNA damage.

CoQ10A cofactor your mitochondria use to move electrons and produce energy.

Functional capacity

VO₂max / Zone-2 thresholdThe functional read-out of mitochondrial fitness - measured during graded exercise testing. As mitochondria adapt, the point where your body shifts from burning fat to burning carbohydrate moves, reflecting better aerobic capacity. A physical metric, not a blood test.

Routine safety

Fasting glucose & CMPStandard metabolic and organ-function checks.

When the tests happen

BaselineHorvath clock, telomere length, 8-OHdG, CoQ10, lactate/pyruvate, CMP.

Through the protocolSymptom and energy tracking; routine glucose/CMP.

Month 6Repeat Horvath clock + key markers to judge progress.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Synthetic tetrapeptide (Ala-Glu-Asp-Gly)
Studied mechanism	Proposed telomerase/pineal effects - largely from a limited regional research group
Human pharmacokinetics	Not characterised in robust peer-reviewed literature
Evidence base	Sparse, largely single-group; not independently well-replicated
Form	Lyophilized powder, reconstituted under clinical protocol
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Evidence is sparse and not independently replicated - stated honestly rather than overclaimed. Educational only.

Clinical Literature

Peer-Reviewed References

Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis, telomerase activity and lifespan in mice

Anisimov VN, Khavinson VKh, Popovich IG, et al. · 2003 · Mechanisms of Ageing and Development 2003;124:225–230

▾

Findings

Methodology note: animal study (CBA mice) from the Russian research group that originally proposed Epithalon. Reported telomerase modulation and reduction in spontaneous tumour incidence over the lifespan of the animals. Findings are preclinical only and have not been independently replicated by investigators outside the originating group. Translation to human clinical outcomes has not been demonstrated.

View on publisher ↗

Peptide bioregulators: A new class of geroprotectors. Report 2: Clinical studies

Khavinson VKh, Morozov VG · 2003 · Advances in Gerontology / Uspekhi Gerontologii 2003;13:36–55

▾

Findings

Methodology note: long-term observational study from the same originating research group, conducted in Russian gerontological practice. Reported reductions in observed mortality and improvements in immunological and metabolic markers in the treated cohort. Important limitations: the study originates from the group commercially associated with the peptide; methodology, randomisation, and blinding documentation are limited; the work has not been independently replicated in peer-reviewed Western literature. Findings should be interpreted with these constraints clearly in mind, not as established efficacy.

View on publisher ↗

Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells

Khavinson VK, Bondarev IE, Butyugov AA · 2003 · Bulletin of Experimental Biology and Medicine 2003;135(6):590–592 (PMID 12937682)

▾

Findings

The originating-group study most cited for Epithalon: in telomerase-negative human fetal fibroblast culture, Epithalon induced expression of the telomerase catalytic subunit (hTERT), telomerase enzymatic activity, and telomere elongation - interpreted as reactivation of the telomerase gene in somatic cells. In vitro; from the Khavinson (St. Petersburg) group, so read alongside the independent-replication study below.

View on publisher ↗

Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

Al-Dulaimi S, Thomas R, Matta S, Roberts T · 2025 · Biogerontology 2025;26:178 (Brunel University London; PMID 41240216)

▾

Findings

The first substantive INDEPENDENT (non-Khavinson) Western replication. In normal human cells (mammary epithelial HMEC, IBR.3 fibroblasts) at 1 µg/mL for 3 weeks, Epitalon produced dose-dependent telomere extension via hTERT/telomerase upregulation. Notably, in breast-cancer lines (21NT, BT474) it lengthened telomeres via ALT (alternative lengthening) rather than telomerase - and ALT was NOT activated in normal cells, which the authors frame as suggesting safety in healthy cells. Important limit: entirely in vitro; no effect sizes/p-values in the abstract; does not establish the effect in living human tissue, and no human trial has measured telomere length before/after Epitalon.

View on publisher ↗

Epithalon's evidence base originates predominantly from a single research group (Anisimov, Khavinson and colleagues) and has not been independently replicated in peer-reviewed Western literature. Proposed mechanisms (telomerase modulation, circadian-rhythm effects) remain hypotheses supported primarily by preclinical work from that group. Vivre presents these references honestly - including the methodology limitations - rather than elevating contested single-group work to the same evidence weight as approved-class trials. Allocation, if any, is physician-supervised with explicit consent that addresses the evidence limitations.

◇

Clinical Applications

Indications

Longevity protocols
Pineal-circadian axis support
Component of Temporal Anchor (V-04)
Telomere-focused interventions

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

Short plasma half-life (minutes). Proposed mechanism involves gene-expression modulation; biological effects (if real) would persist through gene-expression changes beyond peptide clearance. Note: independent Western RCT data on duration of biological effect is limited - see Clinical Literature for evidence framing.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Extensive Russian research literature. Limited Western clinical trials. Strong preclinical and animal longevity data.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including Epithalon

◎

Commonly Paired

Compounds Often Prescribed With Epithalon

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Metabolic Signaler

MOTS-c

Mitochondrial-Derived Peptide · 10mg

◆ longevity pair

MOTS-c's mitochondrial AMPK signaling complements Epithalon's telomerase and circadian mechanism - central to Vivre's V-04 longevity protocol.

View MOTS-c detail →

Mitochondrial Protectant

SS-31

Elamipretide · 10mg

◆ longevity trio

SS-31 protects mitochondrial cardiolipin while Epithalon addresses pineal-axis regulation - divergent mechanisms within V-04's longevity composition.

View SS-31 detail →

Sleep Regulator

DSIP

Delta Sleep-Inducing Peptide · 10mg

◆ sleep - two timescales

Epithalon and DSIP are the long-term and short-term ends of the sleep question. Epithalon acts on the pineal/circadian system over weeks (reported to restore rhythmic melatonin in aging models; single-lab and Soviet-cohort evidence, so honestly tiered), with no immediate sedative effect. DSIP is the acute counterpart - studied as a same-night modulator, though its controlled human evidence is mixed and it remains investigational. They answer different problems (broken circadian rhythm vs. a single bad night), not the same one. Sequence and suitability are clinical decisions.

View DSIP detail →

READY TO PROCEED

Start with the Biological Audit

Epithalon is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$55 USD/vial

Epithalon · Member rate